No rPFS benefit in ph III trial for Abemaciclib in combination with Abiraterone for treatment of mCRPC patients. OncoAlert UroToday.com Jacob Plieth investor.lilly.com/news-releases/…

EV and pembrolizumab doubling PFS and OS in 1st line UC compared to chemotherapy NEJM

EV-302 (EV+P vs chemo 1L treatment in mUC) finally published in NEJM ! Outstanding OS benefit (31 vs 16 months) nejm.org/doi/full/10.10…

« Cette organisation n'est pas seulement inutile. Elle est nocive pour la société »... A lire absolument, cette effarante enquête d'Olivier Hertel sur l’Ordre des médecins, qui a érigé corporatisme et impunité en dogmes. w.lpnt.fr/2556655t via Le Point

⚡️ Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial #BladderCancer #Immunotherapy Journal of Clinical Oncology ascopubs.org/doi/pdfdirect/…

KEYNOTE-564 trial: Improved survival in renal-cell cancer after 1 year of adjuvant therapy was seen with pembrolizumab. At 4 years, 91% of pembrolizumab-treated patients were alive, as compared with 86% of those who received placebo after surgery. nej.md/3TVLuKz

📣Le CARPEM organise le 14 juin 2024 un congrès grand public sur l'IA, un nouvel outil au service de la lutte contre le cancer. Nous vous y attendons nombreux, n'hésitez pas à diffuser cette information autour de vous! Programme et inscription gratuite 👉siric-carpem.e-congres.com/fr/

✏Contribuez | Nous évaluons le #médicament PLUVICTO (Lutécium (177Lu) vipivotide tétraxétan) renouvellement en accès précoce post-AMM pour le traitement du cancer de la #prostate métastatique résistant à la castration progressif positif... swll.to/uhBMT

TROPICS-4 (sacituzumab govitecan vs chemo) in heavily pretreated bladder cancer missed OS. Many drugs have failed in this space (personal experience +++). Managing toxicity is important. Earlier treatment & combinations may yield different results #ASCO24 gilead.com/news-and-press…

JUST IN: Durvalumab extends EFS and OS In muscle-invasive bladder cancer —major news with IO moving earlier stages in balder cancer ! OncoAlert Oncology Times Oncology Brothers Tom Powles Targeted Oncology OncLive.com astrazeneca.com/media-centre/p…

Une jeune fille contacte le 3018 ☎️ car un garçon la menace de diffuser ses n*des 🔞

Campagne de lutte contre l’antisémitisme réalisée grâce à ⁦Arthur_Officiel⁩ et Maurice Lévy pour la ⁦Licra⁩ . Bravo pour ce film fort en ce #14Juillet Liberté Égalité Fraternité

#ARANOTE positive #darolutamide Ph III trial in mHSPC OncoAlert ESMO - Eur. Oncology #ESMO24 neal shore Neeraj Agarwal, MD, FASCO businesswire.com/news/home/2024…®-darolutamide-from-Phase-III-trial-in-men-with-metastatic-hormone-sensitive-prostate-cancer-mHSPC

CHMP gives a positive recommendation for Enfortumab Vedotin and Pembrolizumab in 1st line advanced UC. Paving the way for use in Europe. merck.com/news/merck-rec…

France just won the #Paris2024 gold medal in rugby sevens and then did this !!!

C’est déjà la fin de ces Jeux Olympiques historiques. 💔 On a vécu des moments d’émotion et de beauté absolument surréalistes. Alors je vous propose de les revivre ensemble ! THREAD des moments sportifs les plus marquants de ces Jeux de #Paris2024. 👇

J&J's Balversa earns EU nod as first precision therapy for FGFR3-altered bladder cancer firstwordpharma.com/story/5888528

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

Thread of satisfying photos for perfectionists 1. Moon bridge

Just in 👉 Journal of Clinical Oncology Benefit of Whole-Pelvis Radiation ☢️ for Patients With #MIBC ascopubs.org/doi/10.1200/JC… 👇👇👇TWEETORIAL 👇👇👇